https://orcid.org/0009-0000-7844-3504
References
- Yang F, Wang Q, Deng F, Liu J. CA125-associated activated partial thromboplastin time and thrombin time decrease in patients with adenomyosis. J Multidiscip Healthc. 2024;17(January):251–261. doi:10.2147/JMDH.S435365
- Luo X, Lin X, Lin R, et al. The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer. BMC Cancer. 2023;23(1):1–9. doi:10.1186/s12885-023-11346-8
- Qin YY, Wu YY, Xian XY, et al. Single and combined use of red cell distribution width, mean platelet volume, and cancer antigen 125 for differential diagnosis of ovarian cancer and benign ovarian tumors. J Ovarian Res. 2018;11(1):4–9. doi:10.1186/s13048-018-0382-3
- Winarno GNA, Hidayat YM, Soetopo S, Krisnadi SR, Tobing MDL, Rauf S. The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers. BMC Res Notes. 2020;13(1):1–7. doi:10.1186/s13104-020-05188-x